Accelerating patient recruitment across India's site network

Ask a room of clinical operations leaders what most often derails a trial timeline and the answer is remarkably consistent: recruitment. Industry analyses repeatedly find that a large majority of studies fail to enrol on schedule, and that a meaningful share of sites enrol either no patients at all or a single patient. Every week a study spends waiting for participants is a week of burn with no data to show for it — and, for the sponsor, a week of lost exclusivity on the far side of approval. Recruitment is not a downstream operational detail. It is one of the central determinants of whether a program succeeds.

India occupies a distinctive position in this landscape. It combines large, diverse and treatment-accessible patient populations with a mature ecosystem of investigators trained to ICH-GCP standards and regulatory oversight that has matured considerably over the past decade. For many therapeutic areas — metabolic disease, oncology, infectious disease, women's health — the country offers the ability to reach the right patients at a scale and pace that is difficult to match elsewhere. But that potential is only realised when feasibility, site selection and enrolment tracking are handled with discipline.

Voxtur's model is built around a standing network of more than 75 hospitals and site-management organisations, each with a registered ethics committee and access to a pool of over 125 trained investigators across therapeutic areas. The value of a network like this is not simply its size — it is that feasibility can be answered with real data rather than optimism. When a protocol arrives, the relevant question is not "can we find sites?" but "which of our sites has demonstrably seen this patient population, and how quickly did they enrol in comparable studies?". Answering that early prevents the single most expensive recruitment mistake: activating sites that were never going to deliver.

Realistic feasibility depends on interrogating eligibility criteria against the reality of the clinic. A protocol that looks elegant on paper can be quietly unenrollable if its inclusion and exclusion criteria, taken together, exclude most of the patients who actually present. The most valuable contribution a CRO can make at protocol design is often uncomfortable: to show the sponsor, with site-level data, that a particular washout requirement or biomarker threshold will shrink the eligible pool below what the timeline assumes. Adjusting criteria before first-patient-in is cheap. Discovering the problem three months into enrolment, and running a protocol amendment to fix it, is not.

Once a study is live, enrolment has to be managed as an active process rather than observed as a passive statistic. That means weekly visibility of screening and randomisation by site, rapid identification of sites falling behind their commitments, and a willingness to intervene — with additional recruitment support, community outreach, or in some cases the addition of new sites — before the curve flattens. Enrolment problems compound: a site that starts slowly rarely accelerates on its own, and the cost of waiting to act is almost always higher than the cost of acting.

There is also a human dimension that the operational metrics can obscure. Patients enrol, and stay enrolled, when participation is made comprehensible and respectful — when consent is genuinely informed, when visit schedules acknowledge the realities of people's lives, and when sites are resourced to support participants rather than merely process them. Retention is recruitment's quiet twin; a study that enrols quickly but loses participants to dropout has not solved its problem, only relocated it.

The through-line is simple to state and demanding to execute: recruitment strategy belongs in the protocol, not after first-patient-in. Designing eligibility against real-world site data, selecting sites on evidence rather than reputation, and tracking enrolment as a live operational discipline are what separate studies that read out on time from studies that slip by quarters. In a country with India's clinical depth, the constraint is rarely the availability of patients. It is the rigour with which the pathway to those patients is planned.